MedWatch: FDA Safety Information and Adverse Event Reporting Program
\Increased Energy Expenditure: Tirzepatide boosts fat oxidation
Contact your GP, trial team, or call NHS 111 promptly if you experience: Diarrhoea that is severe, bloody, or persists for more than 4872 hours without improvement Signs of dehydration, including dizziness, reduced urine output, dry mouth, or confusion Significant abdominal pain, particularly if severe or radiating to the back this may rarely indicate pancreatitis, a recognised risk associated with GLP-1-based therapies Pain in the upper right abdomen, fever, or yellowing of the skin or eyes (jaundice) these may suggest gallbladder disease, another recognised complication of this drug class [23] [24] Severe constipation, abdominal distension, or inability to pass wind or stools these may rarely indicate intestinal obstruction or ileus, for which the MHRA and EMA have issued safety communications in relation to GLP-1 receptor agonists [11] [12] Unexplained weight loss beyond what is expected from the treatment Vomiting that prevents adequate fluid or food intake Call 999 or go to your nearest A&E immediately if symptoms are severe, rapidly worsening, or you are unable to keep any fluids down
The Triple-Agonist Changing Weight Loss in 2026 Retatrutide is the most powerful weight loss peptide in 2026 a triple-agonist targeting GLP-1, GIP, and glucagon
Warning signs you are eating too little Watch for these indicators that your calorie intake has dropped too low: Persistent fatigue beyond normal adjustment periods
